Dr. Donovan is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
150 South Huntington Avenue
Boston, MA 02130Phone+1 617-323-7700- Is this information wrong?
Education & Training
- Brigham and Women's HospitalFellowship, Gastroenterology, 1989 - 1990
- Brigham and Women's HospitalResidency, Internal Medicine, 1984 - 1987
- Harvard Medical SchoolClass of 1984
Certifications & Licensure
- MA State Medical License 1986 - 2025
- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Gastroenterology
Publications & Presentations
PubMed
- Assessing the ability of boys with Duchenne muscular dystrophy age 4-7 years to swallow softgel capsules: Clinical trial experience with edasalonexentMaria Cecilia Mancini, Gigi Shafai, Elizabeth Thaler, Joanne M. Donovan, Richard S. Finkel> ;Journal of Clinical Pharmacy and Therapeutics. 2021 Jul 14
- 12 citationsA Randomized, Double-Blind, Placebo-Controlled, Global Phase 3 Study of Edasalonexent in Pediatric Patients with Duchenne Muscular Dystrophy: Results of the PolarisDMD...Richard S. Finkel, Craig M. McDonald, H. Lee Sweeney, Erika Finanger, Erin Neil Knierbein, Kathryn R. Wagner, Katherine D. Mathews, Warren Marks, Jeffrey Statland, Jes...> ;Journal of Neuromuscular Diseases. 2021 Jan 1
- 16 citationsDisease-modifying effects of edasalonexent, an NF-κB inhibitor, in young boys with Duchenne muscular dystrophy: Results of the MoveDMD phase 2 and open label extension...Richard S. Finkel, Erika Finanger, Krista Vandenborne, H. Lee Sweeney, Gihan Tennekoon, Perry B. Shieh, Rebecca J. Willcocks, Glenn A. Walter, William D. Rooney, Sean ...> ;Neuromuscular Disorders. 2021 Feb 4
- Join now to see all
Press Mentions
- Edgewise Therapeutics Announces Initiation of LYNX Phase 2 Clinical Trial of EDG-5506 for the Treatment of Duchenne Muscular Dystrophy (DMD)October 28th, 2022
- EDG-5506 Shows Promise at Reducing Becker MD Muscle DamageOctober 20th, 2022
- EDG-5506 Shows Promise at Reducing Becker MD Muscle DamageOctober 20th, 2022
- Join now to see all
Grant Support
- Pilot Study--Mechanisms Of Cytoprotection By Hydrophilic Bile SaltsNational Institute Of Diabetes And Digestive And Kidney Diseases1994–1998
Hospital Affiliations
- Boston Medical CenterBoston, Massachusetts
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: